Singapore, January 12, 2021 – Genesis Healthcare Asia Pte. Ltd. announces a partnership with Kalgen Innolab in Indonesia.
The partnership covers the introduction of direct-to-consumer genetic testing service in the Indonesian market under Kalgen Innolab’s brand fitGENME.
Leveraging the genetic science and expertise of Genesis Healthcare, the customized service is a PCR based genetic test with focus on diet and sports. Participants are provided with insights and personalized wellness information to enhance their diet and sports regimen based on genetics.
“We are incredibly pleased to partner with Kalgen Innolab to introduce direct-to-consumer genetic testing services in Indonesia and drive the adoption of personalized wellness through diet and sports. With a great understanding of the market and extensive reach, Kalgen Innolab is well placed to successfully launch fitGENME in the market”, commented Michel Mommejat, General Manager of Genesis Healthcare Asia.
Additionally, Henry Sukardi, from Director of Kalgen Innolab mentioned “We are committed to improve health for a better life for the community, we encourage Indonesia citizens to understand the importance of genetic testing which can provide personalized solution for their health and wellness. With more than 935,000 customers who undertook their DNA journey with Genesis Healthcare, we are very thrilled to have such an established partner to introduce our fitGENME services in Indonesia”.
About Genesis Healthcare Co. Ltd
Genesis Healthcare Co., Ltd. is a leading biotech company, pioneering genetic research since 2004 and promoting preventive healthcare and wellness through genetic testing. Leveraging more than 16 years of genetic research and development, Genesis Healthcare empowers medical institutions and end consumers alike to evolve towards personalized wellness and medicine. Originated in Japan, Genesis Healthcare offers medical, corporate, and consumer services through a range of innovative services across the Asia Pacific region.
About Kalgen Innolab
Kalgen Innolab Clinical Laboratory is the first joint foreign investment in clinical laboratories between Indonesia and Japan, and has obtained the approval of Ministry of Health of Republic of Indonesia in line with the Minister of Health Regulation Number 411/MENKES/PER/III/2010 about Clinical Laboratory. PT Innolab Sains Internasional is a joint venture company of PT Kalbio Global Medika (Kalbe’s subsidiary), Toyota Tsusho Corporation (TTC) and Health Science Research Institute, Inc. (HSRI), calling ‘Hoken Kagaku’ in Japanese.